Allergic disorders

When John Bostock first described hay fever in 1819 the condition was rare, but allergy has now reached epidemic proportions, with almost one in two people in the developed world exhibiting an allergic response to some common environmental factor. Most allergic diseases are linked to atopy, the predisposition to generate the allergic antibody IgE to common environmental agents. Because IgE is able to sensitise mast cells anywhere in the body, atopic individuals often express disease in more than one organ. Although current treatments are able to control symptoms, allergy still causes appreciable misery. There is an urgent need for new approaches to more effectively treat allergic responses and prevent their occurrence. This review focuses on some exciting new developments based on a clearer understanding of the underlying cellular and mediator mechanisms and how the human body interacts with the changing environment.

[1]  P. Holt,et al.  Role of microbial burden in aetiology of allergy and asthma , 1999, The Lancet.

[2]  Neumann,et al.  Mechanisms of deficient interferon‐γ production in atopic diseases , 1999 .

[3]  D I Stuart,et al.  Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. , 1999, Molecular cell.

[4]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[5]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[6]  Terán Chemokines and IL‐5: major players of eosinophil recruitment in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  F. Patalano Injection of anti-IgE antibodies will suppress IgE and allergic symptoms. , 1999, Allergy.

[8]  J. Peat,et al.  Reversing the trend: reducing the prevalence of asthma. , 1999, The Journal of allergy and clinical immunology.

[9]  H. Wagner,et al.  Bacterial CpG DNA activates immune cells to signal infectious danger. , 1999, Advances in immunology.

[10]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[11]  S. Durham,et al.  Immunologic changes associated with allergen immunotherapy. , 1998, The Journal of allergy and clinical immunology.

[12]  J. Bousquet,et al.  Clinical efficacy of sublingual‐swallow immunotherapy: a double‐blind, olacebo‐controlled trial of a standardized five‐grass‐pollen extract in rhinitis , 1998, Allergy.

[13]  E. Bröcker,et al.  An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. , 1998, Journal of immunology.

[14]  Epitope-specific antibody response to IgE by mimotope immunization. , 1998, Journal of immunology.

[15]  G. Rook,et al.  Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae , 1998, Immunology.

[16]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[17]  M. Danzig,et al.  Inhibition of interleukin‐5 with a monoclonal antibody attenuates allergic inflammation , 1997, Allergy.

[18]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[19]  G. V. van Seventer,et al.  Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. , 1997, Journal of immunology.

[20]  C. Mackay,et al.  Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. , 1997, The Journal of clinical investigation.

[21]  T. Shirakawa,et al.  The Inverse Association Between Tuberculin Responses and Atopic Disorder , 1996, Science.

[22]  W. Sebald,et al.  Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. , 1994, European journal of biochemistry.

[23]  D. Stanworth,et al.  Allergy treatment with a peptide vaccine , 1990, The Lancet.